Driving performance in the morning after bedtime vornorexant administration: A randomized clinical trial using a driving simulator.

ABSTRACT:

Aim

Sedative hypnotics can impair driving performance to a degree comparable to blood alcohol concentrations of 0.05%-0.08%. This study aimed to evaluate the residual effect of vornorexant, a novel orexin receptor antagonist, on next morning driving performance relative to a predefined clinically meaningful threshold.

Methods

Participants received 10 and 20 mg of vornorexant and placebo for eight consecutive nights and zopiclone on Days 1 and 8 in a four-way crossover and double-blind manner. Driving performance at 9-h post-dose was assessed measuring the standard deviation of the lateral position (SDLP) on Days 2 and 9 (days after single and repeated administration) using a validated driving simulator. Pharmacokinetics were also evaluated.

Results

Sixty-one participa

SUBMITTER: Miyazaki Y 

PROVIDER: S-EPMC12580603 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature